Anteris Technologies (ASX: AVR) — Company Overview, News & Financial Data
Anteris Technologies is focused on structural heart solutions, with its DurAVR™ THV valve mimicking human aortic valve performance.
Anteris Technologies
Anteris Technologies is a structural heart company focused on developing novel medical devices for heart valve replacement and repair. The company's lead product candidate is the DurAVR Transcatheter Heart Valve, a biomimetic single-piece aortic valve designed to restore native laminar blood flow patterns in patients suffering from severe aortic stenosis. Anteris utilizes its proprietary ADAPT tissue engineering technology, an advanced anti-calcification process, to improve tissue durability and bio-integration in cardiovascular applications. The company conducts international clinical trials to support global regulatory approvals and advancement of its cardiovascular therapeutic platform.
Snapshot
Operations
Products and/or services of Anteris Technologies
- Transcatheter Heart Valves: Single-piece native-shaped biomimetic aortic valves engineered to restore healthy physiologic laminar blood flow patterns in adult patients undergoing transcatheter aortic valve replacement for treatment of severe aortic stenosis.
- Tissue Treatment Technology: Proprietary anti-calcification tissue processing platforms designed to optimize bovine pericardium durability, biocompatibility, and hemodynamic performance for structural heart valve implants and general soft tissue surgical reconstruction applications.
- Valve Delivery Systems: Specialized catheter delivery tools developed to facilitate precise anatomical positioning, controlled deployment, and commissural alignment of transcatheter heart valves during minimally invasive cardiovascular surgical procedures across global clinical sites.
- Global Clinical Studies: Multi-center clinical trials evaluating post-procedure aortic blood flow, hemodynamics, safety profiles, and left ventricular mass regression using cardiac MRI across medical centers in North America and Europe.
- Surgical Reconstruction Patches: Processed biological tissue repair products incorporating anti-calcification treatment for cardiovascular reconstruction, vascular repair, dura mater reinforcement, and general soft tissue surgical applications in international medical and hospital environments.
- Cardiac Imaging and Analytics: Specialized diagnostic evaluations utilizing cardiac MRI metrics to quantify post-implantation laminar flow, pressure gradients, effective orifice area, and long-term cardiac remodeling in heart valve replacement cohorts.
Anteris Technologies executive team
- Mr. Wayne Geoffrey PatersonVice Chairman & CEO
- Mr. David St. DenisPresident & Director
- Mr. Matthew McDonnellChief Financial Officer
- Dr. Chris Meduri M.D., M.P.H.Chief Medical Officer & Member of Medical Advisory Board